Compare Ginkgo Bioworks Holdings Inc (DNA) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs HSBC Holdings plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.9 (market cap $590.53M), while HSBC Holdings plc trades at $99.86 (market cap $337.30B). The key difference: HSBC Holdings plc is far larger — about 571.2× Ginkgo Bioworks Holdings Inc's market cap, and HSBC Holdings plc pays a 3.78% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | HSBC | |
|---|---|---|
Market Cap | $590.53M | $337.30B |
Sector | Health | Technology |
52-Week High | $16.14 | $99.25 |
52-Week Low | $5.48 | $61.30 |
Enterprise Value | $627.78M | — |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
HSBC trades at $98.09, down 1.01% today but near its 52-week high of $99.47. Technical indicators show a bullish trend with strong moving average support. The bank reported $71.02B revenue and $22.29B net income for 2025, maintaining a robust 30.81% net margin. Recent news highlights strategic moves including AI partnerships with Google Cloud and potential divestitures of non-core units like its Turkey business.
HSBC presents a balanced investment case with steady profitability and strategic refocusing, but faces risks from global economic sensitivity and regulatory challenges. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
